hepatic clearance

hepatic clearance

Therapeutics The hypothetical calculation of the volume of distribution in liters of unmetabolized drug cleared through the liver in 1 min–L/min. See Clearance.
References in periodicals archive ?
Exact pathogenic mechanism involved is unknown till date, however the basic processes are failure of hepatic clearance of gut derived substances such as ammonia, free fatty acids, mercaptans etc.
The serum markers of fibrosis can be affected by disturbed metabolism as they are the end products of synthesis or breakdown of extracellular matrix and may represent impaired hepatic clearance.
The findings, reported at the annual Digestive Disease Week, should help allay fears that decreased hepatic clearance of statins could lead to complications in patients with advanced liver disease, as was previously hypothesized, said lead investigator Dr.
The findings should allay fears that decreased hepatic clearance of statins could lead to complications in patients with advanced liver disease, said lead investigator Dr.
After administration of appropriate dose this imaging helps to assess Hepatic uptake, Hepatic clearance, etc.
Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis.
Introducing concepts in ways that do not require an intensive mathematical background, he covers the pharmacokinetic behavior of drugs administered intravenously, orally and by intravenous infusion, addressing principles and then the specifics of single intravenous administration, drug absorption following oral administration (including biopharmaceutical considerations and rates), steady states during multiple drug administrations, renal drug elimination, metabolic pharmacokinetics, disease state and drug pharmacokinetics, nonlinear pharmacokinetics, multi-component pharmacokinetic models, intermittent intravenous infusion, data analysis, physiological approaches to hepatic clearance, and the relationship between pharmacokinetics and pharmacodynamics and therapeutic drug monitoring.
This is consistent with other evidence (Schmucker 2001) and suggests that multiple factors such as less blood flow to the liver, smaller liver mass, and decreased specific content of CYPs may combine in elderly individuals to decrease hepatic clearance of drugs.
Spitz finds disconcerting because of the drug's narrow therapeutic range, complex pharmacokinetics, associated accelerated bone loss, and reduced hepatic clearance in the elderly.
enzyme activity As hepatic clearance of drugs is determined by the
The hepatic clearance of drugs can be reduced in elderly people owing to age-associated declines in liver size and blood flow (36).